{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:30:06Z","timestamp":1789695006434,"version":"4.0.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.intimp.2020.106427","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T22:53:14Z","timestamp":1585608794000},"page":"106427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy"],"prefix":"10.1016","volume":"83","author":[{"given":"Maria V.","family":"Deligiorgi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Siasos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysovalantis","family":"Vergadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios T.","family":"Trafalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2020.106427_b0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.intimp.2020.106427_b0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Can. Treat. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2020.106427_b0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy\u2014immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.intimp.2020.106427_b0020","unstructured":"https:\/\/medi-paper.com\/us-fda-approved-immune-checkpoint-inhibitors-approved-immunotherapies\/#toggle-id-2 (Accessed September 20, 2019)."},{"issue":"3","key":"10.1016\/j.intimp.2020.106427_b0025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"issue":"2","key":"10.1016\/j.intimp.2020.106427_b0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2017","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106427_b0035","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"12","author":"Abdel-Rahman","year":"2016","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2020.106427_b0040","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles' heel of cancer immunotherapy?","volume":"23","author":"June","year":"2017","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.intimp.2020.106427_b0045","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.intimp.2020.106427_b0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5049\/EBP.2006.4.2.66","article-title":"Hypernatemia: successful treatment","volume":"4","author":"Kim","year":"2006","journal-title":"Electrolyte Blood Press"},{"key":"10.1016\/j.intimp.2020.106427_b0055","doi-asserted-by":"crossref","unstructured":"Sanders LR. Water Metabolism. In: McDermott MT Endocrine Secrets 6th Edition. Elsevier, Saunders; 2013. p. 198\u2013219.","DOI":"10.1016\/B978-1-4557-4975-1.00033-4"},{"key":"10.1016\/j.intimp.2020.106427_b0060","unstructured":"A.G. Robinson, The Posterior Pituitary (Neurohypophysis), in: D.G. Gardner, D. Shoback, Greenspan's Basic and Clinical Endocrinology, 9th ed. Mc Graw-Hill Lange, 2011, pp. 115\u2013128."},{"issue":"6","key":"10.1016\/j.intimp.2020.106427_b0065","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1590\/2359-3997000000072","article-title":"Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response","volume":"59","author":"Murdaca","year":"2015","journal-title":"Arch Endocrinol. Metab."},{"key":"10.1016\/j.intimp.2020.106427_b0070","unstructured":"A. Prete, R. Salvatori, Hypophysitis. 2018 Aug 15. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519842\/ (Accessed September 15 2019)."},{"issue":"5","key":"10.1016\/j.intimp.2020.106427_b0075","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1272\/jnms.84.201","article-title":"Review on recent topics in hypophysitis","volume":"84","author":"Sugihara","year":"2017","journal-title":"J. Nippon Med. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2020.106427_b0080","doi-asserted-by":"crossref","first-page":"E946","DOI":"10.1210\/jc.2014-4209","article-title":"Rabphilin-3A as a targeted autoantigen in lymphocytic infundibulo-neurohypophysitis","volume":"100","author":"Iwama","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.intimp.2020.106427_b0085","doi-asserted-by":"crossref","unstructured":"M.N. Joshi, B. Whitelaw, P.V. Carroll, Management of endocrine disease: hypophysitis \u2013 diagnosis and treatment, Eur. J. Endocrinol. 2018;179:R151\u201363.","DOI":"10.1530\/EJE-17-0009"},{"issue":"3","key":"10.1016\/j.intimp.2020.106427_b0090","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/EJE-13-0434","article-title":"Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses","volume":"179","author":"Torino","year":"2013","journal-title":"Eur. J. Endocrinol."},{"issue":"14","key":"10.1016\/j.intimp.2020.106427_b0095","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.intimp.2020.106427_b0100","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3390\/ijms20102560","article-title":"Autoimmune endocrine dysfunctions associated with cancer immunotherapies","volume":"20","author":"Ferrari","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2020.106427_b0105","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.intimp.2020.106427_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports","volume":"5","author":"Tan","year":"2019","journal-title":"Clin. Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106427_b0115","doi-asserted-by":"crossref","first-page":"pky021","DOI":"10.1093\/jncics\/pky021","article-title":"The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management","volume":"2","author":"Girotra","year":"2018","journal-title":"JNCI Can. Spectr."},{"key":"10.1016\/j.intimp.2020.106427_b0120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12902-015-0062-x","article-title":"Clinical course of IgG4-related hypophysitis presenting with focal seizure and relapsing lymphocytic hypophysitis","volume":"15","author":"Ngaosuwan","year":"2015","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.intimp.2020.106427_b0125","doi-asserted-by":"crossref","unstructured":"Faje A. Hypophysitis: evaluation and management. Clin. Diabetes Endocrinol. 2 (2016) 15.","DOI":"10.1186\/s40842-016-0034-8"},{"issue":"230","key":"10.1016\/j.intimp.2020.106427_b0130","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.intimp.2020.106427_b0135","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.intimp.2020.106427_b0140","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"issue":"47","key":"10.1016\/j.intimp.2020.106427_b0145","doi-asserted-by":"crossref","first-page":"76565","DOI":"10.18632\/oncotarget.12088","article-title":"Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors","volume":"7","author":"Mei","year":"2016","journal-title":"Oncotarget"},{"issue":"8330","key":"10.1016\/j.intimp.2020.106427_b0150","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0140-6736(83)91328-4","article-title":"Autoantibodies to vasopressin cells in idiopathic diabetes insipidus: evidence for an autoimmune variant","volume":"321","author":"Scherbaum","year":"1983","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.intimp.2020.106427_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112322","article-title":"The hypothalamic pituitary axis and autoantibody related disorders","volume":"18","author":"Cocco","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2020.106427_b0160","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1210\/jc.2012-2269","article-title":"Involvement of hypothalamus autoimmunity in patients with autoimmune hypopituitarism: role of antibodies to hypothalamic cells","volume":"97","author":"De Bellis","year":"2012","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"10","key":"10.1016\/j.intimp.2020.106427_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102363","article-title":"Autoimmune phenomena involving the pituitary gland in children: new developing data about diagnosis and treatment","volume":"18","author":"Romano","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2020.106427_b0170","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1507\/endocrj.EJ17-0028","article-title":"Usefulness of anti-rabphilin-3A antibodies for diagnosing central diabetes insipidus in the third trimester of pregnancy","volume":"64","author":"Sakurai","year":"2017","journal-title":"Endocr. J."},{"issue":"4","key":"10.1016\/j.intimp.2020.106427_b0175","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Can. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2020.106427_b0180","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr. Relat. Can."},{"issue":"1","key":"10.1016\/j.intimp.2020.106427_b0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"issue":"8","key":"10.1016\/j.intimp.2020.106427_b0190","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.6004\/jnccn.2014.0105","article-title":"Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash","volume":"12","author":"Nallapaneni","year":"2014","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"2","key":"10.1016\/j.intimp.2020.106427_b0195","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1210\/jc.2017-01905","article-title":"Anti-PD-L1 treatment induced central diabetes insipidus","volume":"103","author":"Zhao","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.intimp.2020.106427_b0200","doi-asserted-by":"crossref","DOI":"10.1530\/EDM-17-0146","article-title":"Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies","author":"Gunawan","year":"2018","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"10.1016\/j.intimp.2020.106427_b0205","unstructured":"Treatment of central diabetes insipidus. Available from http:\/\/www.uptodate.com. Accessed on 2019 February 12."},{"issue":"10","key":"10.1016\/j.intimp.2020.106427_b0210","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1507\/endocrj.EJ11-0029","article-title":"A case of central diabetes insipidus following probable type A\/H1N1 influenza infection","volume":"58","author":"Kobayashi","year":"2011","journal-title":"Endocr J"},{"issue":"6","key":"10.1016\/j.intimp.2020.106427_b0215","first-page":"1218","article-title":"Vasopressin cell antibodies and central diabetes insipidus in a patient with systemic lupus erythematosus and dermatomyositis","volume":"31","author":"Kajiyama","year":"2004","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106427_b0220","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1530\/EJE-17-0009","article-title":"Mechanisms in endocrinology: hypophysitis: diagnosis and treatment","volume":"179","author":"Joshi","year":"2018","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106427_b0225","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Can."},{"key":"10.1016\/j.intimp.2020.106427_b0230","unstructured":"Management of immunotherpy-Related Toxicities. National Comphrehensive Cancer Network (NCCN) Guidelines. Version 2; 2019. Available from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf (Accessed on 2019 July 24)."},{"key":"10.1016\/j.intimp.2020.106427_b0235","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2020.106427_b0240","doi-asserted-by":"crossref","unstructured":"J.B.A.G. Haanen, F. Carbonnel, C. Robert, et al., 2017. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4) (2017) iv119\u2013iv142.","DOI":"10.1093\/annonc\/mdx225"},{"issue":"18","key":"10.1016\/j.intimp.2020.106427_b0245","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2020.106427_b0250","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1100\/tsw.2010.24","article-title":"Lymphocytic hypophysitis: differential diagnosis and effects of high-dose pulse steroids, followed by azathioprine, on the pituitary mass and endocrine abnormalities\u2013report of a case and literature review","volume":"10","author":"Curto","year":"2010","journal-title":"ScientificWorldJournal"},{"issue":"4","key":"10.1016\/j.intimp.2020.106427_b0255","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11102-014-0592-7","article-title":"Autoimmune lymphocytic hypophysitis in association with autoimmune eye disease and sequential treatment with infliximab and rituximab","volume":"18","author":"Xu","year":"2015","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.intimp.2020.106427_b0260","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/apjon.apjon_3_19","article-title":"Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines","volume":"6","author":"Trinh","year":"2019","journal-title":"Asia Pac. J. Oncol. Nurs."},{"key":"10.1016\/j.intimp.2020.106427_b0265","doi-asserted-by":"crossref","unstructured":"X. Si, P. Song, J. Ni, Management of immune checkpoint inhibitor-related adverse events: a review of case reports. Thorac Cancer. 2020. doi: 10.1111\/1759-7714.13315. [Epub ahead of print].","DOI":"10.1111\/1759-7714.13315"},{"issue":"5","key":"10.1016\/j.intimp.2020.106427_b0270","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3747\/co.25.4235","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a brief review","volume":"25","author":"Myers","year":"2018","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.intimp.2020.106427_b0275","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1148\/radiology.153.2.6484177","article-title":"The pituitary fossa. A correlative anatomic and MR study","volume":"153","author":"Mark","year":"1984","journal-title":"Radiology"},{"issue":"10","key":"10.1016\/j.intimp.2020.106427_b0280","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00234-018-2072-7","article-title":"Neuroimaging of central diabetes insipidus-when, how and findings","volume":"60","author":"Adams","year":"2018","journal-title":"Neuroradiology"},{"issue":"1","key":"10.1016\/j.intimp.2020.106427_b0285","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11060-014-1619-7","article-title":"Diabetes insipidus in pediatric germinomas of the suprasellar region: characteristic features and significance of the pituitary bright spot","volume":"121","author":"Kilday","year":"2015","journal-title":"J Neurooncol"},{"issue":"4","key":"10.1016\/j.intimp.2020.106427_b0290","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11102-018-0885-3","article-title":"Presence of the posterior pituitary bright spot sign on MRI in the general population: a comparison between 1.5 and 3T MRI and between 2D\u2013T1 spin-echo- and 3D\u2013T1 gradient-echo sequences","volume":"21","author":"Klyn","year":"2018","journal-title":"Pituitary"},{"issue":"11","key":"10.1016\/j.intimp.2020.106427_b0295","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/adc.65.11.1199","article-title":"Endocrine function and morphological findings in patients with disorders of the hypothalamo-pituitary area: a study with magnetic resonance","volume":"65","author":"Cacciari","year":"1990","journal-title":"Arch. Dis. Child."},{"issue":"7","key":"10.1016\/j.intimp.2020.106427_b0300","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s003300050261","article-title":"Magnetic resonance imaging of posterior pituitary for evaluation of the neurohypophyseal function in idiopathic and autosomal dominant neurohypophyseal diabetes insipidus","volume":"7","author":"Ozata","year":"1997","journal-title":"Eur. Radiol."},{"issue":"5","key":"10.1016\/j.intimp.2020.106427_b0305","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1365-2265.2011.04270.x","article-title":"Anterior hypopituitarism is rare and autoimmune disease is common in adults with idio- pathic central diabetes insipidus","volume":"76","author":"Hannon","year":"2012","journal-title":"Clin. Endocrinol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106427_b0310","first-page":"1309","article-title":"Autosomal dominant familial neurohypophyseal diabetes insipidus caused by a novel nonsense mutation in AVP-NPII gene","volume":"18","author":"Yang","year":"2019","journal-title":"Exp. Ther. Med."},{"issue":"3","key":"10.1016\/j.intimp.2020.106427_b0315","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/BF00588235","article-title":"Magnetic resonance imaging in familial central diabetes insipidus","volume":"33","author":"Miyamoto","year":"1991","journal-title":"Neuroradiology"},{"issue":"2","key":"10.1016\/j.intimp.2020.106427_b0320","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2020.106427_b0325","first-page":"R166","article-title":"Reduced osmotic thirst in healthy elderly men","volume":"261","author":"Phillips","year":"1991","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.intimp.2020.106427_b0330","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3389\/fendo.2019.00630","article-title":"Adipsic diabetes insipidus-the challenging combination of polyuria and Adipsia: a case report and review of literature","volume":"10","author":"Dalan","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"4","key":"10.1016\/j.intimp.2020.106427_b0335","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1297\/cpe.26.197","article-title":"Characteristic clinical features of adipsic hypernatremia patients with subfornical organ-targeting antibody","volume":"26","author":"Nakamura-Utsunomiya","year":"2017","journal-title":"Clin. Pediatr. Endocrinol."},{"key":"10.1016\/j.intimp.2020.106427_b0340","unstructured":"Subfornical organ. Available from http:\/\/www.wikipedia.org (Accessed on 2018 February 14)."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920301065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920301065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:18:27Z","timestamp":1761585507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920301065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":68,"alternative-id":["S1567576920301065"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106427","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106427","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106427"}}